

**ORIGINAL RESEARCH**

# Role of serum magnesium and serum zinc in diabetes type 2 patients with or without microvascular diseases

<sup>1</sup>Dr. Sangeeta Gurjar, <sup>2</sup>Dr. Sonali Kalvade, <sup>3</sup>Dr. Sheya Nagosker

<sup>1</sup>Research Scholar, Department of Biochemistry, Malwanchal University, Indore, Madhya Pradesh, India

<sup>2</sup>Assistant Professor, Department of Biochemistry, Malwanchal University, Indore, Madhya Pradesh, India

<sup>3</sup>Professor, Department of Biochemistry, Index Medical College, Indore, Madhya Pradesh, India

### Corresponding Author

Dr. Sangeeta Gurjar

Research Scholar, Department of Biochemistry, Malwanchal University, Indore, Madhya Pradesh, India

Received: 02 Sept, 2023

Accepted: 25 Sept, 2023

### ABSTRACT

Diabetic patients' life expectancy has increased as a result of advances in therapies and research, as has the elderly population as a whole. Trace element-associated antioxidant enzymes are changed in diabetes. Many cohort studies have indicated that diabetes can disrupt trace element homeostasis. Early abnormalities in particular components may have a significant effect in altering insulin metabolism.

The present study was conducted in the Department of Biochemistry. It was designed to estimate the alterations in the levels of serum Magnesium and Serum Zinc in type 2 diabetes mellitus patients with microangiopathic complications in comparison to those without these complications and their relation with oxidative stress, insulin resistance, and glycaemic control. The aim of this study is to correlate the serum Magnesium and Serum zinc and insulin resistance levels in patients of type 2 diabetes mellitus with and without micro vascular complications.

The study was permitted by the Ethical Committee of Institution. A written informed consent was attained from all the 600 participants, upon fulfilling the inclusion criteria.

We concluded that mean blood magnesium and zinc levels were considerably lower in type 2 diabetics with problems compared to those without difficulties and the control group. These levels declined considerably during the course of diabetes. A momentous negative correlation was showed by Serum levels of Magnesium and Zinc with FBS, HbA1c, HOMA-IR and MDA.

Current observations recommend that Screening panel in the risk detection and progression of diabetes should include the estimation of serum zinc, magnesium and copper estimation. Supplementation of Mg and Zn and recurrent one-to-one care of levels of both minerals in type 2 diabetic patients.

**Key words:** Magnesium, zinc, diabetes, fasting blood sugar, HbA1c

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

### INTRODUCTION

Minerals and traces of elements are critical micronutrients that the body needs to operate properly. These elements are especially useful for physiological processes.<sup>1</sup> Minerals and trace elements are required for many biological reactions, operate as stabilising components of enzymes and proteins, and serve as cofactors for several enzymes. Certain trace elements control critical biological processes by attaching to the receptor location of the cell membrane or altering the shape of the receptor to prevent specific molecules from entering the cell.<sup>2</sup> Micronutrients perform two functions: they keep cellular structures stable at appropriate levels, while deficiency leads to other routes and may cause

illness.<sup>3</sup> These vital micronutrients have significant physiological significance and show direct connections with diabetes.<sup>4,5</sup>

The scientific literature and medical data from diabetes studies provide reasonable estimates of crucial micronutrient deficiency/overload. However, the numerous inconsistencies in research make it difficult for physicians to formulate dietary advice for diabetics.<sup>6</sup> Diabetic patients' life expectancy has increased as a result of advances in therapies and research, as has the elderly population as a whole. Trace element-associated antioxidant enzymes are changed in diabetes.<sup>7</sup> Many cohort studies have indicated that diabetes can disrupt trace element homeostasis.<sup>8</sup> Early abnormalities in particular

components may have a significant effect in altering insulin metabolism<sup>9,10,11</sup>. The bulk of cohort studies concentrate on a single aspect or a small set of components exclusively.

Micronutrients have been recognised as essential nutrients that are required in trace levels for homeostasis, enzyme control, and function.<sup>12,13</sup>

### **ASSOCIATION BETWEEN DIABETES MELLITUS AND ALTERATIONS IN THE METABOLISM OF TRACE ELEMENTS**

Numerous human and animal studies have shown a clear link between mineral metabolism and human health. A change in the metabolism of these elements has frequently been seen. The micronutrient status of patients with diabetes mellitus has changed over the past 60 years, according to numerous studies, and in a few of these studies, a mineral deficiency has been linked to the prevalence of diabetic complications. Contradictory results and opposing conclusions have been produced as a result of methodological flaws and variations in the patient population under study.

Magnesium is the body's fourth most abundant cation and the second most prevalent intracellular cation after potassium. By acting as a cofactor for the various enzymes involved at multiple stages in insulin secretion, binding, and activity, magnesium plays a crucial role in glucose metabolism and the transport of glucose by the cell.<sup>14</sup>

The only transition metal that is present in every type of enzyme is zinc, which is the second most prevalent transition metal in organisms after iron. Zinc, a crucial trace element, is crucial for the synthesis, storage, and release of insulin as well as other tissue-maintaining processes. Additionally, it keeps insulin's structural structure intact. *In vitro* studies have shown that zinc increases the efficiency of insulin, and it has been suggested that a zinc deficit may make non-insulin-dependent diabetes mellitus patients more resistant to insulin.<sup>15</sup>

Since, zinc is a requirement for the enzyme's superoxide dismutase, catalase and peroxidase, changes in zinc metabolism that render sufficient zinc insufficient for these enzymes may be expected to add to the tissue damage seen in diabetes. A higher chance of developing diabetes appears to be associated with low dietary zinc intake. According to a recent meta-analysis, zinc supplementation in diabetic individuals enhances glycaemic control and supports healthy lipid parameters.<sup>16</sup>

The present study is designed in order to estimate the alterations in the levels of serum Magnesium and Serum Zinc in type 2 diabetes mellitus patients with microangiopathic complications in comparison to those without these complications and their relation with oxidative stress, insulin resistance, and glycaemic control. The aim of this study is to correlate the serum Magnesium and Serum zinc and insulin resistance levels in patients of type 2

diabetes mellitus with and without micro vascular complications.

### **MATERIAL AND METHODS**

**SUBJECTS AND STUDY DESIGN:** The present study was conducted in the Department of Biochemistry. The study was permitted by the Ethical Committee of Institution. A written informed consent was attained from all the participants, upon fulfilling the inclusion criteria.

**SELECTION OF SUBJECTS:** In all 600 subjects were in the present study.

**CONTROL GROUP:** 200 healthy age and gender-matched participants were chosen from the workplace. These participants would be non-diabetic, physically active, and had fasting blood glucose levels ranging from 70 to 100 mg%. All patients would be between the ages of 35 and 70. Both sex groups will be included. They will be clear of any serious illnesses that might impact the parameters being studied.

**TEST GROUP-1:** Include 200 type 2 diabetic patients with a duration of less than 5 years. They have no clinical indications of microvascular consequences from diabetes mellitus. Diabetes will be diagnosed using the same criteria established by the World Health Organisation. Diabetes mellitus symptoms include fasting plasma glucose levels of 126 mg/dL or above.

OR test for postprandial plasma glucose levels of 200 mg/dL or above.

**TEST GROUP-2:** The study included 200 type 2 diabetes mellitus patients who had one or more microvascular manifestations of diabetes mellitus. Diabetes lasts five or more years.

To detect microvascular problems, the physician will use the following procedures.

**DIABETIC RETINOPATHY:** A thorough fundus examination was done to look for retinal vascular micro aneurysms, blot and cotton wool spots (non-proliferative diabetic retinopathy) and appearance of neovascularisation (proliferative diabetic retinopathy).

**DIABETIC NEUROPATHY:** A complete motor and sensory examination was carried out to any polyneuropathy, radiculopathy or mono-neuropathy. Diabetic Nephropathy: Urinary micro protein estimation along with serum creatinine was carried out.

**EXCLUSION CRITERIA:** 1. Patients with type I Diabetes Mellitus. 2. Pregnant and lactating females. 3. Patients taking diuretics, lipid-lowering, and multivitamins drugs. 4. Patients with disease unrelated to diabetes which may alter chosen parameters

i.e. AIDS, thyroid disease, tuberculosis, and cancer patients.

#### PARAMETERS PERFORMED

- BIOCHEMICAL PARAMETERS:** Fasting Blood glucose, HbA1C, Serum Magnesium, Serum Zinc.
- SPECIAL PARAMETERS:** Serum insulin, Insulin Resistance.

#### ESTIMATION OF SERUM MAGNESIUM

**METHOD:** Calmagite indicator method (Colorimetric; kits by tulips Diagnostic).

**PRINCIPLE:** Magnesium reacts with calmagite in an alkaline solution to generate a crimson complex. The use of particular chelating agents and detergents eliminates calcium-protein interference. The intensity of the colour produced is exactly proportional to the quantity of magnesium in the sample.

#### ESTIMATION OF SERUM ZINC

**Method:** Nitro-PAPS method (Colorimetric; kits by tulips Diagnostic).

**PRINCIPLE:** Zinc in an alkaline medium reacts with Nitro-PAPS to form a purple-coloured complex. The intensity of the complex formed is directly proportional to the amount of Zinc present in the sample.

#### RESULTS

Out of 600 study population in the age group of 35-70 years, 200 healthy volunteers were chosen as control while 200 T2DM patients without microvascular complications and 200 T2DM patients with microvascular complications were distributed as study group-I and study group-II. Males and females were enrolled in this study in greater proportion than females. Group I had 121 male and 79 female members, Group II had 120 male and 80 female members whereas Group III had 125 male and 75 female members. Within each group, there was a notable distinction between the men and females. The Control group had a mean age of 47.05 was significantly lower than other groups. There was a significant difference compared mean age between the groups.

The control group had normal glucose levels. Both research groups had significantly elevated glucose levels relative to the control group. Group III had higher glucose levels than Groups I and II. The differences between groups were statistically

significant. HbA1C levels increased significantly in both diabetes groups as compared to the control group. Group II exhibited a substantial difference from Group III. Group-III had the greatest rise in HbA1C compared to Groups II and I. Group-I showed a significant difference compared to other groups. Group-III showed maximum insulin level compared to other groups. Both diabetes groups showed a considerable rise in HOMA-IR as compared to control participants. HOMA-IR increased significantly in Group III when compared to the other groups.

Maximum magnesium levels were seen in the control group. Diabetic individuals had significantly lower magnesium levels compared to the control group. A considerable difference was discovered between Groups II and III. Group-I showed high levels of zinc compared to Group-II and III. Control group showed significant difference compared Group-II and III. Least Zinc value was noticed in Group-III. FBS, Zn and PCR shown a significant increase with the duration of onset of diabetes. Highest values of FBS and PCR were noticed in above 3 years duration. While zinc significantly declines with the duration of diabetes.

HbA1C, HOMA-IR, MDA values shown a significant increase with the duration of onset of diabetes. Highest values of HbA1C, HOMA-IR and MDA were, noticed in above 3 years duration. While Magnesium significantly declines with the duration of diabetes.

The distribution of magnesium in controls and test groups. Hypo-magnesium was significantly higher in both study groups compared to control groups. Zinc deficiency was significantly higher in type 2 diabetics with microvascular complication group when compare to control and group II.

Linear regression analyses were performed between magnesium with other variables, in which serum magnesium was the dependent variable and FBS, HbA1C, HOMA-IR, serum

Zinc, MDA and PCR were the independent variables. Revealed that only Serum Zinc was positively correlated while FBS, HbA1C, HOMA-IR, and MDA showed inverse relationships with serum Magnesium. (Table 9)

Linear regression analyses were performed between zinc and other variables, in which serum zinc was the dependent variable and FBS, HbA1C, HOMA-IR, serum Mg, MDA, and PCR were the independent variables. Revealed that only Serum Magnesium and Vitamin D were positively correlated while FBS, HbA1C, HOMA-IR and MDA showed a negative correlation with serum Zinc. (Table 10)

**Table1:** Comparison of fasting blood glucose (mg/dl), HbA1C, Insulin and HOMA-IR levels between the groups

Groups	Description of group	Fasting blood glucose (mg/dl) (MEAN±SD)	HbA1C (MEAN±SD)	Insulin (MEAN±SD)	HOMA-IR (MEAN±SD)
Groups-I	Control	86.17±7.35	5.23±0.51	5.72±0.98	1.33±0.19
Groups-II	T2DM without microvascular complications	140±30.75*	6.87±0.75*	9.98±7.5*	3.89±2.2*
Groups-III	T2DM with microvascular complications	172.56±52.9*#	7.96±1.83*#	11.5±8.55*	5.18±2.6*

(\*p<0.05 significant compared Group-I with other groups, #p<0.05 significant compared Group-II with other Groups).

**Table2:** Comparison of magnesium levels between the groups

Groups	Description of group	Magnesium (Mean±SD)
Group-I	Control	2.13±.27
Group-II	T2DM without microvascular complications	1.77±.25*
Group-III	T2DM with microvascular complications	1.61±.20*#

(\*p<0.05 significant compared Group-I with other groups, #p<0.05 significant compared Group-II with other Groups)

**Table3:** Comparison of Zinc levels between the groups

Groups	Description of group	Zinc (Mean ±SD)
Group-I	Control	99.85±11.35
Group-II	T2DM without microvascular complications	85.59±12.71*
Group-III	T2DM with microvascular complications	73.77±12.37*#

(\*p<0.05 significant compared Group-I with other groups, #p<0.05 significant compared Group-II with other Groups)

**Table4:** Comparison of mean fasting blood glucose, zinc, PCR within the Group-II and III based on the duration of diabetes

Observation	Less than 1 year (Mean ±SD)	1-3 years (Mean ±SD)	Above 3 years (Mean ±SD)
Fasting blood glucose	105.02±1.02	115.12±0.23*	138.20±0.86*#
Zinc	95.86±11.32	89.27±11.87*	75.19±11.88*#
PCR	17.20±4.09	22.89±8.74*	165.49±90.66*#

(\*p<0.05 significant compared less than 1 year with other time periods, #p<0.05 significant compared 1-3 years with other time periods)

**Table5:** Comparison of mean HbA1C, insulin, HOMA-IR, magnesium, MDA within the Group-II and III based on the duration of diabetes

Observation	Less than 1 year (Mean±SD)	1-3 years (Mean±SD)	Above 3 years (Mean±SD)
HbA1C	6.19±0.87	7.90±1.34*	8.87±0.95*#
HOMA-IR	1.57±0.34	3.49±0.43*	4.11±0.45*
Magnesium	1.98±.43	1.70±.58	1.67±0.89*
MDA	1.20±0.32	2.02±0.73	2.49±0.96*

(\*p<0.05 significant compared less than 1 year with other time periods, #p<0.05 significant compared 1-3 years with other time periods)

**Table6:** Comparison of mean magnesium and zinc within the Group-III based on the complications

Observation	Retinopathy (n=73) (Mean±SD)	Nephropathy (n=55) (Mean±SD)	Neuropathy (n=23) (Mean±SD)	Multiple complications (n=49)
Magnesium	1.64±0.19	1.71±0.44*	1.70±0.33*	1.50±0.15*
Zinc	78.40±11.65#	68.78±7.66	83.50±8.86*#	70.29±11.72

(\*p<0.05 significant compared retinopathy with others, #p<0.05 significant compared nephropathy with others)

**Table 7:** Comparison of Magnesium Distribution between the groups

Magnesium levels	Control Number %		Group-II Number %		Group-III Number %	
1.0-1.8	25	(12.5%)	105	(52.5%)	125	(62.5%)
1.8-2.5	168	(84%)	90	(45%)	75	(37.5%)
>2.5	7	(3.5%)	5	(3%)	0	(0%)

**Table 8:** Comparison of Zinc Distribution between the groups

Zinc Levels	Control Number	(n=200) %	Normodiabetic (n=200) Number %		Group-III (n=200) Number %	
<60.	0	0%	06	3%	21	10.5%
60-120	195	97.5%	194	97%	179	89.5%
>120	05	2.5%	00	0%	00	0%

**Table 9:** Correlation of Magnesium with other observations

X-axis numbers	Observation	Pearson correlation	P-value
1	Fasting blood glucose	-0.218*	0.001
2	HBA1C	-0.182*	0.010
3	HOMA-IR	-0.167*	0.014
4	Zinc	0.155*	0.026
5	Copper	-0.162*	0.018
6	Vitamin-D3	0.164*	0.017
7	MDA	-0.289#	0.001
8	PCR	-0.141*	0.03

(\*p<0.05 significant, #p<0.001 significant)

**Table 10:** Correlation of Zinc with other observations

X-axis numbers	Observation	Pearson correlation	P-value
1	Fasting blood glucose	-0.192*	0.006
2	HBA1C	-0.145*	0.039
3	HOMA-IR	-0.171*	0.014
4	Magnesium	0.155*	0.026
5	Copper	-0.165*	0.018
6	Vitamin-D3	0.242#	0.001
7	MDA	-0.260#	0.001
8	PCR	-0.166#	0.002

(\*p<0.05 significant, #p<0.001 significant)

**DISCUSSION**

A series of events leading to micro and macrovascular problems in diabetes, including retinopathy, nephropathy, neuropathy, cardiovascular illnesses, and peripheral vascular diseases, are set off by chronic hyperglycemia. These consequences impact numerous tissues and organs.<sup>17</sup> The etiology of type 2 diabetes is complicated and still unknown. Diabetes and associated consequences might develop more quickly for a variety of reasons. Genetics, age, weight, food, exercise, and pregnancy are a few of them.<sup>18</sup> Magnesium is a necessary element that is vital to both the action of insulin and the metabolism of carbohydrates in general. It contributes to insulin binding, activity, and secretion at several levels. Tyrosine kinase activity is influenced by magnesium, which affects how insulin and glucose are metabolized.<sup>19</sup> It is crucial to the actions of several enzymes involved in the oxidation of glucose.

In this investigation, we discovered that the serum magnesium level in both diabetes groups was substantially lower (P<0.001) than in the control group, and hypomagnesemia was reported in 63% of the study patients compared to 12% of the control group, suggesting that hypomagnesemia is more common in diabetics. This is in line with earlier research that shown type 2 diabetes patients had lower mean plasma magnesium levels and a greater incidence of hypomagnesemia.<sup>20,21</sup> Earlier studies have reported decreased magnesium levels in diabetes by demonstrating reduced levels of Mg in plasma, serum, and erythrocytes.<sup>22,23</sup> The precise cause of behind hypomagnesemia in type-2 diabetes mellitus is not completely clear, but possible causes may include osmotic diuresis causing high renal excretion of magnesium, impaired magnesium absorption and distribution of magnesium from plasma to red blood cells caused by insulin effect.<sup>24</sup>

Type 2 diabetes has been attributed to hypomagnesemia, and glycemic control and FBS seem to be negatively impacted by magnesium shortage. Plasma magnesium levels were shown to be statistically significantly correlated negatively with fasting plasma glucose ( $r = -0.229$ ;  $P < 0.0001$ ) and HbA1c ( $r = -0.193$ ;  $P = 0.010$ ).

In addition, studies also imply a link between magnesium deficiency and insulin resistance. Mg deficiency decreases insulin sensitivity via an alteration of the insulin-receptor associated tyrosine kinase in type-2 diabetes.<sup>14</sup> This is supported by present results when serum mg levels were negatively correlated with HOMA-IR ( $r = -0.172$ ;  $P = 0.014$ ).

According to our research, type 2 diabetes patients with microvascular difficulties had serum magnesium levels that were considerably lower than those of T2DM patients without microvascular issues ( $P = 0.025$  and Mean difference 0.67; Table 4.24 & Figure 4.8). Similar findings were reported by Baig *et al.* (2012), who hypothesized that hypomagnesemia would cause microvascular problems by inhibiting the action of the prostacyclin receptor, resulting in an imbalance between the effects of prostacyclin and thromboxane. This imbalance has a strong atherogenic potential.

We found a statistically significant negative correlation between serum Mg level with urinary albumin/creatinine ratio ( $r = -0.140$ ;  $P = 0.004$ ) This is consistent with the results of Arpacietal, 2015 and Corica *Fetal.*, 2006.<sup>25,26</sup>

A highly significant correlation was found between the variables in our study, which included malondialdehyde as the dependent variable and magnesium as the independent variable. This suggests that a deficiency in magnesium may contribute to increased oxidative stress and decreased antioxidant potential. It is consistent with the prior research conducted in 2002 by Hans CP *et al.*<sup>27</sup>

In their investigations, Deng *et al.* (2006) and Kelishadi R *et al.* (2014) examined the possible roles that magnesium consumption, either on its own or in combination with vitamin D intake, may play in maintaining vitamin D status. Additionally, we discovered in this investigation that serum magnesium and vitamin D3 positively correlated.<sup>28,29</sup>

Zinc is a necessary trace element that aids in the production, storage, and secretion of insulin as well as maintaining the hexameric form of insulin's structure.<sup>30</sup>

Furthermore, zinc has a dynamic function as a "cellular second messenger" in the regulation of glucose homeostasis and insulin signalling, as demonstrated by recent investigations. The human body has a strictly controlled concentration of zinc, and disruptions in zinc homeostasis have been linked to a number of illnesses, including diabetes mellitus.<sup>31</sup> Numerous studies have documented the relationship between zinc metabolism and the metabolic and biochemical elements implicated in the

pathophysiology of type 2 diabetes mellitus. The majority of them stated that low zinc status had accelerated the development of diabetes.<sup>20</sup>

The result of the present study explain zinc levels in diabetics (both with complications and without complications) were lower than the control group. This finding was in agreement with the findings of Meenakshi T, 2016; Puri *et al.*, 2013, Walter *et al.*, 1991.<sup>32,20,33</sup> The fact that hyperglycaemia in diabetes is typically linked to hyperzincuria and increased urine zinc loss, which causes reductions in total body zinc, might be one explanation for this. Disrupted zinc metalloenzyme metabolisms and aberrant zinc binding to tissue proteins, which results in hyperzincuria, are two more potential reasons. However, contradictory results were also noticed in other studies according to which there was no significant difference in serum zinc levels among the type 2 diabetic patients.<sup>34</sup>

Zinc demonstrated a strong negative correlation with FBS, HbA1c, and HOMA-IR. These results are consistent with those of Kamal *et al.* (2009). This is explained by zinc's function in regulating insulin synthesis through pancreatic tissue and glucose utilization through muscles and fat cells. Hyperglycemia results from zinc deficiency, and the ability to synthesize and produce insulin, as well as consume glucose, is compromised.<sup>35</sup>

Our investigation revealed a significant negative connection between Zn and MDA ( $r < 0.001$ ). This conclusion is consistent with that of Kamal *et al.* (2009) who concluded that Zn metabolism plays a role in antioxidant mechanisms. It might also be supported by the presence of Zn in numerous antioxidant enzymes, including catalase, peroxidase, and dismutase. As a result, zinc deficiency may cause oxidative stress, which is responsible for the majority of diabetic problems.<sup>35</sup>

Zinc is a retinal protective factor, by stabilizing the membrane structure, activating metallothionein, clearing free radicals and inhibiting lipid peroxidation, it may reduce the expression of vascular endothelial growth factor, and inhibit the neovascularization and exudation (Miao X *et al.*, 2014). This is supported by our present results where we found lower zinc levels in DR patients than in those without DR. Suggesting that zinc might play an important role in the development of DR.<sup>36</sup>

Our study also found that individuals with increased urine ACR had considerably lower zinc levels, with those with an ACR greater than 300 mg/g having the lowest zinc levels in serum. Our findings also indicated that serum zinc levels were an independent risk factor for DN. Our study also found that zinc levels were considerably lower in diabetic neuropathy patients. Diabetic neuropathy was mostly caused by oxidative stress.

## Conclusion

The mean blood magnesium and zinc levels were considerably lower in type 2 diabetics with problems compared to those without difficulties and the control group. These levels declined considerably during the course of diabetes. A momentous negative correlation was showed by Serum levels of Magnesium and Zinc with FBS, HbA1c, HOMA-IR, and MDA. Current observations recommend that Screening panel in the risk detection and progression of diabetes should include the estimation of serum zinc, magnesium and copper estimation. Supplementation of Mg and Zn and recurrent one-to-one care of levels of both minerals in type 2 diabetic patients.

## References

1. Calabrese E.J., Canada A.T., Sacco C. Trace Elements and Public Health. *Annu. Rev. Public Health*. 1985;6:131-146.
2. Young V.R. Trace element biology: The knowledge base and its application for the nutrition of individuals and populations. *J. Nutr.* 2003;133(Suppl. 1):1581S-1587S.
3. Nordberg M., Nordberg G.F. Trace element research-historical and future aspects. *J. Trace Elements Med. Boil.* 2016;38:46-52.
4. Uğurlu V., Binay C., Şimşek E., Bal C. Cellular Trace Element Changes in Type 1 Diabetes Patients. *J. Clin. Res. Pediatr. Endocrinol.* 2016;8:180-186.
5. Zhang H., Yan C., Yang Z., Zhang W., Niu Y., Li X., Qin L., Su Q. Alterations of serum trace elements in patients with type 2 diabetes. *J. Trace Elements Med. Boil.* 2017;40:91-96.
6. Siddiqui K., Bawazeer N., Joy S.S. Variation in Macro and Trace Elements in Progression of Type 2 Diabetes. *Sci. World J.* 2014;2014:1-9.
7. Badran M., Morsy R., Soliman H., Elnimr T. Assessment of trace elements levels in patients with Type 2 diabetes using multivariate statistical analysis. *J. Trace Elements Med. Boil.* 2016;33:114-119.
8. Wolide A.D., Zawdie B., Alemayehu T., Tadesse S. Association of trace metal elements with lipid profiles in type 2 diabetes mellitus patients: A cross sectional study. *BMC Endocr. Disord.* 2017;17:64.
9. Sun W., Yang J., Wang W., Hou J., Cheng Y., Fu Y., Xu Z., Cai L. The beneficial effects of Zn on Akt-mediated insulin and cell survival signaling pathways in diabetes. *J. Trace Elements Med. Boil.* 2018;46:117-127.
10. Zhang Q., Sun X., Xiao X., Zheng J., Li M., Yu M., Ping F., Wang Z., Qi C., Wang T., et al. Dietary Chromium Restriction of Pregnant Mice Changes the Methylation Status of Hepatic Genes Involved with Insulin Signaling in Adult Male Offspring. *PLoS ONE.* 2017;12:e0169889.
11. Tinkov A.A., Sinitskii A., Popova E., Nemereshina O., Gatiatulina E., Skalnaya M.G., Skalny A.V., Nikonorov A. Alteration of local adipose tissue trace element homeostasis as a possible mechanism of obesity-related insulin resistance. *Med. Hypotheses.* 2015;85:343-347.
12. Kashiv Y., Austin J.R., Lai B., Rose V., Vogt S., El-Muayed M. Imaging trace element distributions in single organelles and subcellular features. *Sci. Rep.* 2016;6:21437.
13. Koekkoek W.A., Van Zanten A.R. Antioxidant Vitamins and Trace Elements in Critical Illness. *Nutr. Clin. Pract.* 2016;31:457-474.
14. Barbagallo M, Dominguez LJ. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. *Arch Biochem Biophys* 2007; 458: 40-47
15. Praveena S., Sujatha PaSula , K. Sameera. Trace Elements in Diabetes Mellitus. *Journal of Clinical and Diagnostic Research.* 2013 Sept, Vol-7(9): 1863-1865
16. Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. *DiabetolMetab Syndr.* 2012;4 (1):13.
17. Crispin JC, Alcocer-Varela J, de Pablo P, Martínez A, Richaud-Patin Y, Alarcón Segovia D. Immunoregulatory effects in patients with systemic lupus erythematosus in clinical remission. *Lupus.* 2003;12(5):386-93.
18. George L King. The Role of Inflammatory Cytokines in Diabetes and Its Complications. *Journal of periodontology.* August 2008 Volume 79, Issue 8S Pages 1527-1534.
19. Volpe, S.L. Magnesium in disease prevention and overall health. *Advances in Nutrition.* 2013.
20. Puri C, Renna M, Bento CF, Moreau K, Rubinsztein DC. Diverse autophagosome membrane sources coalesce in recycling endosomes. *Cell.* 2013;154(6):1285-1299. Doi:10.1016/j.cell.2013.08.044
21. Pham PC, Pham P M, Pham S V, Miller J M, Pham P T. Hypomagnesemia in patients with type 2 diabetes. *Clin J Am Soc Nephrol* 2007;2: 366373pmid:17699436
22. Ankush, R. D., Suryakar, A. N., & Ankush, N. R. Hypomagnesaemia in type-2 diabetes mellitus patients: a study on the status of oxidative and nitrosative stress. *Indian journal of clinical Biochemistry*, 2009, 24(2), 184-189.
23. Heba M. Yossefa, Nashwa S. Ghanema, Ula M. Al-Jarhia, Ollfat G. Shakerb. Relation of serum magnesium level to microvascular complications and the components of metabolic syndrome in patients with type 2 diabetes mellitus. *Egypt J Intern Med.* 2017;29:100-104.
24. Hussain F, M Arif Maan, MA Sheikh, H Nawaz, A Jamil. Trace elements status in type 2 diabetes. *Bangladesh Journal of Medical Sciences* 2009;8 (3): 5256

25. Arpaci D, Tocoglu AG, Ergenc H, Korkmaz S, Ucar A, Tamer A. Associations of serum Magnesium levels with diabetes mellitus and diabetic complications. *Hippokratia*. 2015; 19(2):153-157.
26. Corica F, Corsonello A, Ientile R, Cucinotta D, Di Benedetto A, Perticone F, et al. Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. *J Am Coll Nutr* 2006; 25:210-215.
27. Hans CP, Sialy R, Bansal D. Magnesium deficiency and diabetes mellitus. *Curr Sci*. 2002;83:145-663
28. Deng X, Song Y, Manson JE, Signorello LB, Zhang SM, Shrubsole MJ, *et al.* Magnesium, vitamin D status and mortality: Results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. *BMC Med*. 2013;11:187.
29. Kelishadi R, Ataei E, Ardalan G, *et al.* Relationship of Serum Magnesium and Vitamin D Levels in a Nationally-Representative Sample of Iranian Adolescents: The CASPIAN-III Study. *International Journal of Preventive Medicine*. 2014;5(1):99-103.
30. Tripathy S, Sumanth S, Bhupal Raj G. Mineral Nutritional Status of type 2 diabetic subjects. *Int J Diab Devlp Ctries* 2004;24:27-8
31. Gandhi M, Dhananjayan R, Swaminathan S. The Significance and Importance of Vitamin D and Zinc in Type 2 Diabetes Mellitus. *IJRSB Volume 3, Issue 8, August 2015*,
32. Meenakshi Puri, Uma Gujral, S.B. Nayyar. Comparative study of serum zinc, magnesium and copper levels among patients of type 2 diabetes mellitus with and without microangiopathic complications. *ijmhs*. 3:6 November-December (2013) 274278
33. Walter RM, Uri Hare JY, Olin KL. Copper, zinc, manganese and magnesium status and complications of diabetes mellitus. *Diabetes Care* 1991;14:1050-56.
34. Diwan AG, Pradhan AB, Linogjwar D, Krishna KK, Singh P, Almelkar SI. Serum zinc, chromium and magnesium levels in type 2 diabetes. *Int J Diab Devlp. Ctries*. 2006;26(3):122-23. 31.
35. Kamal M, Salem M, Kholousi N, Ashmawy K. Evaluation of trace elements and malondialdehyde levels in type 2 diabetes mellitus. *Diabetes Metab Syndr Clin Res Rev*. 2009;3:21-48.
36. Miao X, Sun W, Miao L, Fu Y, Wang Y, Su G, *et al.* Zinc and diabetic retinopathy. *J Diabetes Res* 2013;2013:425-854.